Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder

NCT ID: NCT00741598

Last Updated: 2017-05-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 72 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-09-30
• Study Completion Date: 2014-05-31

Brief Summary

This study will examine whether extended release galantamine, a drug approved by the Food and Drug Administration to reduce cognitive impairments in people with Alzheimer's disease, can perform the same function in stable people with bipolar disorder.

Detailed Description

Approximately 2.6% of Americans age 18 and older, or 5.7 million people, suffer from bipolar disorder. The manic and depressive episodes associated with bipolar disorder prevent normal functioning in individuals with the disorder, but functional impairment can occur even when bipolar disorder is in remission. Previous research indicates that this impairment in stable individuals with bipolar disorder is linked to neurocognitive deficits, such as problems with memory and attention. The drug extended release galantamine increases the level of acetylcholine, a neurotransmitter important for memory, available in the brain. This drug has already been approved by the FDA to treat neurocognitive impairment in Alzheimer's disease patients. This study will examine whether administering the drug to individuals with bipolar disorder who are in remission can also reduce their neurocognitive deficits and improve the quality of their life. The study will also examine the safety of the drug for use in the obsessive-compulsive disorder population.

Participation in this study will last about 18 weeks and will involve six study visits. Each of the first two visits will include 2 hours of clinical, physical, and self-report tests, the first for screening and the second to establish physical and mental health baseline measurements. Participants will then be randomly assigned to receive either galantamine or placebo daily for 16 weeks, and they will be provided with enough of the assigned pill to last until the next visit. Half hour visits on Weeks 4, 8, and 12 will consist of psychological self-report tests and interviews, clinical assessment of side effects from the drug, and the determination by the examining doctor and participant whether to increase, decrease, or maintain the same level of the drug. Participants will also be given enough of the drug to last until the next visit. The final visit, on Week 16, will last 2 hours and will consist of the same tests administered at the baseline visit in addition to the neuropsychological tests administered at the screening visit. The full range of tests will measure physical health, verbal memory, mental flexibility, attention, life impairment, and life satisfaction.

Conditions

Bipolar Disorder

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Galantamine-ER

Participants will receive treatment with extended release galantamine

Group Type: EXPERIMENTAL

Galantamine-ER

Intervention Type: DRUG

Galantamine-ER 8 to 24 mg per day for 16 weeks

Galantamine placebo

Participants will receive treatment with placebo.

Group Type: PLACEBO_COMPARATOR

Galantamine placebo

Intervention Type: DRUG

Galantamine placebo 8 to 24 mg per day for 16 weeks

Interventions

Galantamine-ER

Galantamine-ER 8 to 24 mg per day for 16 weeks

Intervention Type: DRUG

Galantamine placebo

Galantamine placebo 8 to 24 mg per day for 16 weeks

Intervention Type: DRUG

Other Intervention Names

Razadyne-ER; placebo

Eligibility Criteria

Inclusion Criteria

• DSM-IV diagnosis of Bipolar I disorder or Bipolar II disorder
• A baseline Hamilton-D 17 score of less than 10 at screening visit
• A baseline Young Mania Rating Scale (YMRS) score of less than 10 at screening visit
• No acute episodes of depression or mania for the previous 12 weeks
• Score of 17 or higher on the Massachusetts General Hospital (MGH) Cognitive and Physical Functioning Questionnaire
• Treated with psychiatric medications, alone or in combination, having only minimal, mild or moderate cognitive burden [as determined by a score of less than 3.5 on the MGH Cognitive Impact of Psychotropic Medications Scale (CIPMS).
• Able to understand English

Exclusion Criteria

• DSM-IV diagnosis of Bipolar NOS, Cyclothymia, or Schizoaffective Bipolar type.
• Meets DSM-IV criteria for acute manic, depressive, or mixed bipolar episode or had met full criteria for 2 consecutive weeks within the past 12 weeks prior to assessment
• Treated with psychiatric medications with large effects on cognition (as determined by a MGH Cognitive Impact of Psychotropic Medications Scale score of 4.0 or above)
• Pregnant women or women of child bearing potential who are not using a medically accepted means of contraception (defined as oral contraceptive pill or implant, condom, diaphragm, spermicide, IUD, s/p tubal ligation, partner with vasectomy)
• Serious suicide or homicide risk
• Unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease.
• History of seizure disorder, brain injury, or any known neurological disease (multiple sclerosis, degenerative disease such as ALS, Parkinson disease and any movement disorders, etc)
• The following DSM-IV diagnoses: 1) organic mental disorders; 2) any diagnosis of dementia; 3) substance use disorders, including alcohol, active within the last year; 4) schizophrenia; 5) delusional disorder; 6) psychotic disorders not elsewhere classified; 7) schizoaffective disorder; 8) major depressive disorder; 9) acute bereavement; 10) severe borderline or antisocial personality disorder
• Presence of mood congruent or mood incongruent psychotic features
• Clinical or laboratory evidence of hypothyroidism
• History of multiple adverse drug reactions, allergy to galantamine or other AChEIs
• Current use, or use within the last week, of excluded drugs (psychotropic medications and other central nervous system (CNS)-active drugs)
• Taken an investigational psychotropic drug within the last year
• Had electroconvulsive therapy (ECT) within the 6 months preceding enrollment

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Mental Health (NIMH)

NIH

Sponsor Role: collaborator

Massachusetts General Hospital

OTHER

Sponsor Role: collaborator

Icahn School of Medicine at Mount Sinai

OTHER

Sponsor Role: lead

Responsible Party

Dan V. Iosifescu

M.D., M.Sc.

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Dan V. Iosifescu, MD

Role: PRINCIPAL_INVESTIGATOR

Icahn School of Medicine at Mount Sinai & Massachusetts General Hospital

Locations

Massachusetts General Hospital

Boston, Massachusetts, United States

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Countries

United States

Other Identifiers

R01MH079157

Identifier Type: NIH

Identifier Source: secondary_id

View Link

1R01MH079157-01A2

Identifier Type: NIH

Identifier Source: secondary_id

View Link

DATR A5-ETMA

Identifier Type: -

Identifier Source: secondary_id

GCO 10-1060

Identifier Type: -

Identifier Source: org_study_id